| Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial O Hermine, X Mariette, PL Tharaux, M Resche-Rigon, R Porcher, ... JAMA internal medicine 181 (1), 32-40, 2021 | 927 | 2021 |
| Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial PL Tharaux, G Pialoux, A Pavot, X Mariette, O Hermine, M Resche-Rigon, ... The Lancet Respiratory Medicine 9 (3), 295-304, 2021 | 296 | 2021 |
| A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma E Bachy, S Le Gouill, R Di Blasi, P Sesques, G Manson, G Cartron, ... Nature Medicine 28 (10), 2145-2154, 2022 | 258 | 2022 |
| Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients—a multinational observational study by the European Confederation of … J Prattes, J Wauters, DR Giacobbe, J Salmanton-García, J Maertens, ... Clinical Microbiology and Infection 28 (4), 580-587, 2022 | 195 | 2022 |
| Outcomes of patients with aggressive B-Cell lymphoma after failure of anti-CD19 CAR T-Cell Therapy: A DESCAR-T analysis R Di Blasi, S Le Gouill, E Bachy, G Cartron, D Beauvais, F Le Bras, ... Blood, 2022 | 86 | 2022 |
| Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and/or malignant hematological disorders JJ Tudesq, G Cartron, S Rivière, D Morquin, L Iordache, A Mahr, ... Autoimmunity reviews 17 (2), 115-124, 2018 | 62 | 2018 |
| Sepsis and Septic Shock in Patients With Malignancies: A Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique Study V Lemiale, S Pons, A Mirouse, JJ Tudesq, Y Hourmant, D Mokart, F Pène, ... Critical Care Medicine 48 (6), 822-829, 2020 | 57 | 2020 |
| Invasive Pulmonary Aspergillosis in Nonimmunocompromised Hosts JJ Tudesq, O Peyrony, V Lemiale, E Azoulay Seminars in Respiratory and Critical Care Medicine 40 (04), 540-547, 2019 | 54 | 2019 |
| Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial X Mariette, O Hermine, PL Tharaux, M Resche-Rigon, R Porcher, ... The Lancet Rheumatology 4 (1), e24-e32, 2022 | 42 | 2022 |
| Impact of prone position in non-intubated spontaneously breathing patients admitted to the ICU for severe acute respiratory failure due to COVID-19 R Jouffroy, M Darmon, F Isnard, G Geri, A Beurton, M Fartoukh, JJ Tudesq, ... Journal of critical care 64, 199-204, 2021 | 36 | 2021 |
| Infectious events in patients with severe COVID-19: results of a cohort of patients with high prevalence of underlying immune defect A Saade, G Moratelli, G Dumas, A Mabrouki, JJ Tudesq, L Zafrani, ... Annals of intensive care 11 (1), 83, 2021 | 28 | 2021 |
| Clinical and Product Features Associated with Outcome of DLBCL Patients to CD19-Targeted CAR T-Cell Therapy S Lamure, F Van Laethem, D De Verbizier, C Lozano, E Gehlkopf, ... Cancers 13 (17), 4279, 2021 | 28 | 2021 |
| FIRST RESULTS OF DLBCL PATIENTS TREATED WITH CAR‐T CELLS AND ENROLLED IN DESCAR‐T REGISTRY, A FRENCH REAL‐LIFE DATABASE FOR CAR‐T CELLS IN HEMATOLOGIC MALIGNANCIES S Le Gouill, E Bachy, R Di Blasi, G Cartron, D Beauvais, F Le Bras, ... Hematological Oncology 39, 2021 | 21 | 2021 |
| Cytomegalovirus Infection With Retinitis After Brentuximab Vedotin Treatment for CD30+ Lymphoma JJ Tudesq, L Vincent, J Lebrun, Y Hicheri, L Gabellier, T Busetto, C Merle, ... Open Forum Infectious Diseases 4 (2), ofx091, 2017 | 21 | 2017 |
| Coagulation disorders in patients with severe hemophagocytic lymphohistiocytosis S Valade, BS Joly, A Veyradier, J Fadlallah, L Zafrani, V Lemiale, ... PloS one 16 (8), e0251216, 2021 | 16 | 2021 |
| Microbial translocation is correlated with HIV evolution in HIV-HCV co-infected patients JJ Tudesq, C Dunyach-Remy, C Combescure, R Doncesco, D Laureillard, ... Plos one 12 (9), e0183372, 2017 | 15 | 2017 |
| Prise en charge prophylactique, thérapeutique des complications infectieuses et vaccination des patients traités par CAR-T cells: recommandations de la Société francophone de … F Paul, C Vicente, C Courbon, AS Moreau, M Picard, C Pochon, A Sterin, ... Bulletin du Cancer 108 (12), S90-S97, 2021 | 12* | 2021 |
| A Propensity Score-Matched Comparison of Axi-Cel and Tisa-Cel for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Real-Life: A Lysa Study from the Descar-T Registry E Bachy, S Le Gouill, R Di Blasi, P Sesques, G Cartron, D Beauvais, ... Blood 138 (Supplement 1), 92-92, 2021 | 12 | 2021 |
| Diagnostic strategy for trigger identification in severe reactive hemophagocytic lymphohistiocytosis: A diagnostic accuracy study JJ Tudesq, S Valade, L Galicier, L Zafrani, D Boutboul, C de Bazelaire, ... Hematological Oncology 39 (1), 114-122, 2021 | 9 | 2021 |
| Management of cytokine release syndrome and macrophage activation syndrome following CAR-T cell therapy: Guidelines from the SFGM-TC JJ Tudesq, M Yakoub-Agha, JO Bay, C Courbon, F Paul, M Picard, ... Bulletin du Cancer 110 (2S), S116-S122, 2021 | 8* | 2021 |
